Phospho-CFL1/CFL2 (Tyr88) Antibody

What is Phospho-CFL1/CFL2 (Tyr88) Antibody and what does it specifically detect?

Phospho-CFL1/CFL2 (Tyr88) Antibody is a rabbit polyclonal antibody specifically designed to detect endogenous levels of cofilin1/cofilin2 only when phosphorylated at tyrosine 88 (pTyr88) . The antibody was developed using a synthetic phosphopeptide immunogen with the sequence around the phosphorylation site of tyrosine 88 (A-T-Y(p)-E-T) derived from human cofilin1/cofilin2 . This high-specificity antibody enables researchers to distinguish the phosphorylated form of cofilin at this particular residue from unphosphorylated cofilin or cofilin phosphorylated at other sites. The production process typically involves immunizing rabbits with the synthetic phosphopeptide conjugated to KLH (Keyhole Limpet Hemocyanin) followed by affinity purification using epitope-specific phosphopeptide . Importantly, manufacturers remove non-phospho specific antibodies through chromatography using non-phosphopeptide, ensuring the antibody's specificity for the phosphorylated form .

How does Tyr88 phosphorylation differ from Ser3 phosphorylation in cofilin function?

Cofilin regulation through phosphorylation occurs at multiple sites with distinct functional consequences. Phosphorylation at Serine 3 (S3) is well-characterized and known to modulate cofilin's activity in actin filament assembly/disassembly, influencing cellular morphology . When cofilin is phosphorylated at Ser3, its actin-binding ability is inhibited, which prevents actin depolymerization . In contrast, Tyr88 phosphorylation represents a different regulatory mechanism affecting cofilin's interaction with actin. The phosphorylation at Tyr88 occurs within a sequence context (A-T-Y-E-T) that likely influences cofilin's three-dimensional structure and its interaction with actin filaments . While both modifications affect actin dynamics, they likely operate through different signaling pathways and respond to different cellular stimuli. Understanding the differential roles of these phosphorylation sites is crucial for researchers investigating the complex regulation of actin cytoskeleton remodeling in various physiological and pathological contexts . Experimental designs should carefully distinguish between these two phosphorylation events to accurately interpret their respective contributions to cellular processes.

What are the recommended applications and dilutions for Phospho-CFL1/CFL2 (Tyr88) Antibody?

The Phospho-CFL1/CFL2 (Tyr88) Antibody has been validated for multiple experimental applications with specific recommended dilutions for optimal results. For Western blot (WB) analysis, the recommended dilution range is 1:500 to 1:1000, which provides sufficient sensitivity while minimizing background signals . Immunohistochemistry (IHC) applications typically require more concentrated antibody solutions, with recommended dilutions of 1:50 to 1:100 . The antibody has also been validated for Enzyme-Linked Immunosorbent Assay (ELISA) applications, though specific dilution recommendations may vary by manufacturer . Some sources additionally indicate compatibility with Immunofluorescence/Immunocytochemistry (IF/ICC) techniques, with suggested dilution ranges of 1:100 to 1:200 . These applications collectively enable researchers to detect phosphorylated cofilin across multiple experimental platforms, from protein extract analysis to visualization in fixed tissues and cells. When establishing these techniques in a new experimental system, researchers should perform antibody titration experiments to determine the optimal concentration for their specific application and sample type, as factors such as expression levels and sample preparation methods can influence the optimal working dilution.

What species reactivity can be expected with this antibody?

The Phospho-CFL1/CFL2 (Tyr88) Antibody demonstrates confirmed reactivity with human and mouse samples across multiple applications . This cross-species reactivity is expected due to the high degree of conservation in the amino acid sequence surrounding the Tyr88 phosphorylation site between these species. Some product specifications also indicate reactivity with rat samples, expanding its utility for comparative studies across common laboratory rodent models . The conservation of this phosphorylation site across species suggests the functional importance of this regulatory mechanism in actin dynamics. When working with species not explicitly listed in the specifications, researchers should perform validation experiments to confirm cross-reactivity. This validation is particularly important when studying cofilin phosphorylation in non-mammalian models or less commonly used mammalian species. Sequence alignment analysis of the immunogen region can provide preliminary insights into potential cross-reactivity, but experimental confirmation remains essential for definitive determination of antibody suitability across species boundaries.

How should I validate the specificity of Phospho-CFL1/CFL2 (Tyr88) Antibody in my experimental system?

Validating antibody specificity is crucial for ensuring reliable experimental results. For Phospho-CFL1/CFL2 (Tyr88) Antibody, a comprehensive validation approach should include multiple complementary strategies. First, perform comparative Western blot analysis using samples with known phosphorylation status, such as cell lysates treated with phosphatase inhibitors versus phosphatase-treated samples, which should show differential detection . Second, conduct peptide competition assays where pre-incubation of the antibody with the phosphorylated peptide immunogen should abolish signal, while pre-incubation with the non-phosphorylated peptide should not affect detection . Third, implement genetic approaches using cell lines with CRISPR/Cas9-mediated cofilin mutations at Tyr88 (Y88F) that prevent phosphorylation, which should yield negative results with the antibody. Fourth, use siRNA knockdown of relevant kinases responsible for Tyr88 phosphorylation to demonstrate reduced signal intensity. Finally, employ parallel detection methods such as mass spectrometry to independently confirm the presence of phosphorylated Tyr88 in samples showing positive antibody reactivity. This multi-faceted validation approach ensures that the observed signals genuinely represent Tyr88-phosphorylated cofilin rather than non-specific binding or cross-reactivity with other phosphorylated proteins.

What are the optimal sample preparation techniques for detecting Phospho-CFL1/CFL2 (Tyr88) in different experimental contexts?

Successful detection of Phospho-CFL1/CFL2 (Tyr88) requires careful sample preparation that preserves the phosphorylation state while minimizing background interference. For protein extraction, use ice-cold lysis buffers containing phosphatase inhibitors (e.g., sodium orthovanadate, sodium fluoride, and phosphatase inhibitor cocktails) to prevent dephosphorylation during sample processing . RIPA buffer supplemented with these inhibitors is suitable for most applications, though gentler NP-40-based buffers may better preserve protein-protein interactions when needed. For tissue samples, flash-freezing in liquid nitrogen immediately after collection is critical to preserve phosphorylation status, followed by homogenization in phosphatase inhibitor-containing buffers. When preparing samples for immunohistochemistry, use freshly prepared 4% paraformaldehyde for fixation, as extended storage of fixed tissues can reduce phospho-epitope detection . For cell culture experiments investigating signaling dynamics, rapid termination of cellular processes is essential; direct addition of hot SDS sample buffer to cultured cells can effectively "freeze" the phosphorylation state. Additionally, normalization controls should include detection of total cofilin to establish relative phosphorylation levels, particularly when comparing experimental conditions. When working with tissues known to have high phosphatase activity (e.g., brain), consider using phosphatase inhibitor pre-injection before tissue harvesting to maximize phospho-epitope preservation.

How can I troubleshoot weak or absent signals when using Phospho-CFL1/CFL2 (Tyr88) Antibody in Western blots?

Troubleshooting weak or absent signals with Phospho-CFL1/CFL2 (Tyr88) Antibody requires systematic evaluation of each experimental step. First, assess protein extraction efficiency and phosphorylation preservation by checking phosphorylation status of other well-characterized proteins using control antibodies . If phosphorylation is generally preserved, increase antibody concentration, extending from the recommended 1:1000 dilution to 1:500 or even 1:250 for samples with low abundance of phosphorylated cofilin . Extend primary antibody incubation time to overnight at 4°C to enhance binding efficiency, and consider using high-sensitivity detection systems such as chemiluminescent substrates with enhanced formulations. Membrane blocking conditions can significantly impact phospho-epitope detection; try alternative blocking agents like 5% BSA instead of milk, as milk contains phospho-proteins that may interfere with phospho-specific antibody binding. For samples with inherently low phosphorylation levels, consider enriching phospho-proteins using phospho-protein enrichment kits or immunoprecipitation before Western blotting. Additionally, verify that the predicted molecular weight observed matches expectations (approximately 19 kDa for cofilin) . If these approaches fail, consider stimulating your experimental system with treatments known to enhance tyrosine phosphorylation, such as pervanadate treatment or growth factor stimulation, to confirm antibody functionality under conditions that maximize the phosphorylated form.

What is the best approach for quantifying changes in Tyr88 phosphorylation levels in response to experimental treatments?

Accurate quantification of Tyr88 phosphorylation changes requires rigorous experimental design and analysis methodology. The gold standard approach combines Western blotting with densitometric analysis using parallel detection of total cofilin for normalization . When implementing this approach, load equal amounts of total protein (20-50 μg) across all samples, and confirm equal loading using housekeeping proteins like GAPDH or β-actin as additional controls. After immunoblotting, capture images using a digital imaging system with a linear dynamic range, avoiding saturation that would compromise quantification accuracy. For densitometric analysis, measure the integrated density of phospho-cofilin bands and normalize first to the corresponding total cofilin signal in the same sample, then calculate fold changes relative to control conditions. For more precise quantification, consider using multiplex fluorescent Western blotting systems that allow simultaneous detection of phospho-cofilin and total cofilin on the same membrane, eliminating transfer efficiency variations between blots. Alternative quantification methods include ELISA-based approaches using the Phospho-CFL1/CFL2 (Tyr88) Antibody, which can provide higher throughput analysis when processing multiple samples . For single-cell level analysis of phosphorylation heterogeneity, quantitative immunofluorescence microscopy with appropriate controls and standardized image acquisition parameters enables spatial assessment of phosphorylation changes in subcellular compartments that may be masked in whole-cell lysate analyses.

How can I design experiments to investigate the functional consequences of Tyr88 phosphorylation in actin dynamics?

Investigating the functional impact of Tyr88 phosphorylation on actin dynamics requires multi-dimensional experimental approaches. Begin by establishing cellular models with manipulated Tyr88 phosphorylation status through expression of phospho-mimetic (Y88E/Y88D) or phospho-deficient (Y88F) cofilin mutants . These complementary approaches allow distinction between phosphorylation-dependent and independent effects. To visualize real-time actin dynamics, combine these genetic manipulations with live-cell imaging using fluorescently tagged actin (LifeAct-GFP) or photoactivatable actin constructs, quantifying parameters such as actin polymerization rates, filament stability, and retrograde flow. Biochemical actin assays provide complementary quantitative data; perform in vitro actin polymerization/depolymerization assays using purified wild-type or mutant cofilin proteins, measuring changes in pyrene-labeled actin fluorescence to determine how Tyr88 phosphorylation alters cofilin's actin-severing efficiency. For cellular phenotype assessment, analyze migration using wound healing or transwell assays, as cofilin-mediated actin dynamics significantly impact cell motility. Examine morphological changes through quantification of lamellipodial dynamics, filopodial formation, and focal adhesion turnover using immunofluorescence with the Phospho-CFL1/CFL2 (Tyr88) Antibody alongside actin and focal adhesion markers . Additionally, investigate the interplay between Tyr88 and Ser3 phosphorylation by simultaneously monitoring both modifications using specific antibodies under various stimulation conditions, determining whether these modifications occur sequentially, antagonistically, or independently in response to different signaling inputs.

What approaches can distinguish between phosphorylation patterns of CFL1 versus CFL2 isoforms?

Distinguishing phosphorylation patterns between cofilin isoforms presents significant analytical challenges due to their high sequence homology, particularly around the Tyr88 phosphorylation site. A comprehensive approach begins with isoform-specific knockdown experiments using siRNA or shRNA targeting unique regions of CFL1 or CFL2 mRNAs, followed by Western blotting with the Phospho-CFL1/CFL2 (Tyr88) Antibody to determine contribution of each isoform to the total phosphorylation signal . For more definitive analysis, implement isoform-specific immunoprecipitation using antibodies that target unique regions of CFL1 or CFL2, followed by immunoblotting with the phospho-specific antibody. This sequential IP-Western approach allows separate analysis of phosphorylation status for each isoform. Mass spectrometry offers the most discriminating approach; following isoform-specific immunoprecipitation, perform LC-MS/MS analysis focusing on phosphopeptides containing Tyr88, where subtle sequence differences between isoforms enable definitive assignment of phosphorylation to specific cofilin variants. For tissue-specific analysis, combine in situ hybridization for isoform-specific mRNAs with immunohistochemistry using the Phospho-CFL1/CFL2 (Tyr88) Antibody to correlate expression patterns with phosphorylation status in different cell types . Additionally, leverage known differential expression patterns—CFL1 is widely expressed while CFL2 shows muscle-enriched expression—to design tissue-comparative studies where phosphorylation patterns in muscle (expressing both isoforms) versus non-muscle tissues (predominantly CFL1) can reveal isoform-specific regulation patterns under physiological and pathological conditions.

What experimental strategies can reveal the kinases and phosphatases that regulate Tyr88 phosphorylation?

Identifying the regulatory enzymes controlling Tyr88 phosphorylation requires systematic interrogation of candidate kinases and phosphatases. Begin with in silico analysis of the sequence surrounding Tyr88 (A-T-Y-E-T) to identify tyrosine kinase consensus motifs, generating a prioritized list of candidate kinases for experimental validation . Test these candidates through kinase inhibitor screening, treating cells with specific inhibitors followed by Western blot analysis with the Phospho-CFL1/CFL2 (Tyr88) Antibody to detect reduced phosphorylation. Complement pharmacological approaches with genetic manipulation, using siRNA knockdown or CRISPR/Cas9 knockout of candidate kinases, measuring the impact on basal and stimulated Tyr88 phosphorylation levels. For direct biochemical validation, perform in vitro kinase assays using purified candidate kinases and recombinant cofilin substrate, followed by Western blotting or mass spectrometry to confirm Tyr88 phosphorylation. To identify relevant phosphatases, implement similar approaches using phosphatase inhibitors with varying specificity profiles, combined with phosphatase overexpression or knockdown experiments. For systematic discovery of unidentified regulators, perform phosphoproteomic analysis comparing Tyr88 phosphorylation across conditions with differential activation of major signaling pathways, or implement CRISPR screens using the Phospho-CFL1/CFL2 (Tyr88) Antibody in high-content imaging readouts to identify novel regulators. Additionally, investigate the spatiotemporal regulation of Tyr88 phosphorylation through co-localization studies using the phospho-specific antibody alongside candidate kinases and phosphatases under various cellular stimulation conditions, revealing compartmentalized regulation mechanisms that may be masked in whole-cell biochemical analyses.

How can Phospho-CFL1/CFL2 (Tyr88) Antibody be used to investigate disease-relevant dysregulation of cofilin phosphorylation?

The Phospho-CFL1/CFL2 (Tyr88) Antibody represents a valuable tool for investigating disease-relevant alterations in cofilin regulation across multiple pathological contexts. For cancer research, perform comparative analysis of Tyr88 phosphorylation levels between patient-derived tumor samples and matched normal tissues using immunohistochemistry with carefully optimized antibody dilutions (1:50-1:100) . Correlate these findings with clinical parameters such as tumor stage, metastatic status, and patient outcomes to establish potential prognostic value. In neurodegenerative disease models, where actin cytoskeletal abnormalities contribute to pathology, analyze region-specific changes in cofilin phosphorylation using immunohistochemistry and Western blotting of brain subregions, comparing affected versus spared regions . For cardiovascular disorders, investigate how altered hemodynamic forces affect endothelial and smooth muscle cell cofilin phosphorylation patterns using in vitro flow models combined with immunofluorescence detection of phospho-cofilin localization patterns. When studying inflammatory diseases, examine how inflammatory mediators modulate cofilin phosphorylation in immune cells, potentially affecting migration and immune synapse formation. For mechanistic insights, combine these analyses with assessment of upstream signaling pathway activation and downstream functional consequences on actin dynamics specific to each disease context. Additionally, evaluate the therapeutic potential of targeting cofilin phosphorylation by treating disease models with compounds that modulate identified regulatory kinases or phosphatases, using the Phospho-CFL1/CFL2 (Tyr88) Antibody to monitor target engagement and efficacy in normalizing dysregulated phosphorylation patterns associated with pathological states.

How does immunohistochemical detection of Phospho-CFL1/CFL2 (Tyr88) compare between different tissue preparation methods?

Immunohistochemical detection of Phospho-CFL1/CFL2 (Tyr88) can vary significantly depending on tissue preparation methodology, requiring careful optimization for maximum sensitivity and specificity. Formalin-fixed paraffin-embedded (FFPE) tissues offer excellent morphological preservation but may require antigen retrieval methods to expose the phospho-epitope; testing both heat-induced epitope retrieval (HIER) with citrate buffer (pH 6.0) and Tris-EDTA buffer (pH 9.0) is recommended to determine optimal conditions . Perform parallel comparison of retrieval times (10-30 minutes) to balance epitope recovery against tissue integrity preservation. Fresh-frozen sections generally provide superior phospho-epitope preservation but with compromised morphological detail; these samples require careful handling with phosphatase inhibitor inclusion throughout the preparation process. For comparative studies, use standardized fixation times (typically 24 hours for FFPE tissues) across all samples to minimize fixation-dependent variability in antibody penetration and epitope accessibility. When developing detection protocols, compare DAB-based chromogenic detection with fluorescent secondary antibody methods; while DAB offers permanent staining and compatibility with conventional microscopy, fluorescent detection enables multi-label co-localization studies with actin cytoskeleton components. The antibody dilution requires careful optimization for each preparation method; generally, more concentrated antibody solutions (1:50) are needed for FFPE tissues compared to frozen sections . Additionally, implement phospho-specific positive controls (such as phosphatase inhibitor-treated tissues) alongside dephosphorylated negative controls (phosphatase-treated sections) to validate staining specificity across different preparation techniques.

What are the appropriate experimental controls for validating Phospho-CFL1/CFL2 (Tyr88) Antibody results in different applications?

Rigorous experimental controls are essential for validating results obtained with Phospho-CFL1/CFL2 (Tyr88) Antibody across different applications. For Western blotting, include positive controls such as lysates from cells treated with pervanadate (a potent tyrosine phosphatase inhibitor) to maximize tyrosine phosphorylation levels . Corresponding negative controls should include lambda phosphatase-treated samples to demonstrate phosphorylation-dependent detection. For antibody specificity validation, perform peptide competition assays where the antibody is pre-incubated with excess phosphorylated immunogen peptide, which should abolish specific signal while leaving non-specific binding unchanged. In immunohistochemistry applications, incorporate tissue-matched isotype controls using non-specific rabbit IgG at equivalent concentrations to distinguish specific staining from background . When working with genetic models, tissues or cells with CRISPR-mediated mutation of the Tyr88 residue to phenylalanine (Y88F) provide ideal negative controls that maintain protein expression while eliminating the phosphorylation site. For phosphorylation dynamics studies, include time-course controls with appropriate stimuli known to modulate tyrosine phosphorylation pathways. When performing quantitative comparisons, technical replicate controls assess method reproducibility, while biological replicates address natural variation. Additionally, implement antibody cross-reactivity controls by testing detection in samples where either CFL1 or CFL2 has been selectively knocked down, confirming the contribution of each isoform to the observed signal pattern in your specific experimental system.

How can I integrate Phospho-CFL1/CFL2 (Tyr88) Antibody data with other actin dynamics measurement techniques?

Integration of Phospho-CFL1/CFL2 (Tyr88) Antibody data with complementary actin dynamics measurement techniques creates a more comprehensive understanding of cytoskeletal regulation. Begin by establishing temporal correlation between changes in Tyr88 phosphorylation (detected via Western blotting or immunofluorescence) and functional actin dynamics measured through fluorescence recovery after photobleaching (FRAP) of GFP-actin, which quantifies actin turnover rates in living cells . For spatial correlation analysis, perform dual immunofluorescence labeling with the phospho-specific antibody alongside fluorescently-labeled phalloidin to visualize the relationship between phospho-cofilin localization and F-actin structures at high resolution using confocal or super-resolution microscopy. Combine these imaging approaches with biochemical fractionation separating G-actin and F-actin pools, followed by quantification of phospho-cofilin distribution between these fractions via Western blotting. For dynamic studies, implement live-cell imaging using Förster resonance energy transfer (FRET)-based biosensors that report on cofilin activity, correlating these real-time measurements with fixed-cell phospho-cofilin immunostaining at defined timepoints. To connect molecular changes to cellular behavior, perform parallel analysis of cell migration parameters (velocity, directionality, persistence) alongside phospho-cofilin levels under various experimental conditions. For systems-level integration, combine phosphoproteomics data identifying cofilin Tyr88 phosphorylation with transcriptomics and other PTM analyses to place this modification within broader signaling networks regulating cytoskeletal dynamics. Additionally, quantitative mathematical modeling incorporating phosphorylation rate constants and cofilin activity parameters can predict emergent properties of actin network behavior based on experimentally determined Tyr88 phosphorylation levels under different cellular conditions.

What methodological considerations are important when analyzing Phospho-CFL1/CFL2 (Tyr88) in different subcellular compartments?

Analysis of Phospho-CFL1/CFL2 (Tyr88) across subcellular compartments requires specialized methodological approaches to accurately capture spatial regulation patterns. For immunofluorescence microscopy, optimize fixation protocols that preserve both phospho-epitopes and subcellular architecture; paraformaldehyde (4%) fixation for 10-15 minutes generally provides good compromise, while avoiding methanol fixation which can extract phospholipids and disrupt membrane-associated structures . Implement confocal microscopy with appropriate subcellular markers (e.g., DAPI for nucleus, phalloidin for F-actin, specific markers for organelles) to precisely localize phospho-cofilin signals within cellular compartments. For biochemical analysis, perform careful subcellular fractionation to isolate nuclear, cytoplasmic, membrane, and cytoskeletal fractions, followed by Western blotting with the Phospho-CFL1/CFL2 (Tyr88) Antibody; include fraction-specific markers (e.g., lamin for nucleus, GAPDH for cytoplasm) to confirm fractionation quality. When quantifying compartment-specific enrichment, normalize phospho-cofilin signals to total cofilin within each fraction rather than across fractions to account for differential distribution of the total protein. For dynamic translocation studies, establish synchronized cellular systems where stimulation triggers cofilin redistribution, then analyze phosphorylation status across compartments at defined timepoints. Super-resolution microscopy techniques such as STORM or STED provide nanoscale resolution of phospho-cofilin localization relative to actin filaments and regulatory proteins within specific compartments . Additionally, proximity ligation assays (PLA) combining the Phospho-CFL1/CFL2 (Tyr88) Antibody with antibodies against compartment-specific interaction partners can reveal spatially restricted protein-protein interactions that may be specific to particular subcellular locations, providing mechanistic insights into compartmentalized regulation of cofilin phosphorylation and function.